Luye Pharma Group (HKG:2186) raised net proceeds of $98.6 million from the issuance of the first tranche of $100 million 5.85% convertible bonds due 2025, a Wednesday Hong Kong bourse filing said.
The bonds have an initial conversion price of HK$3.672 per share, subject to certain conditions, the filing said.
The company plans to use the net proceeds to settle some of its debts, for research and development, and for general corporate purposes.
The bonds are expected to be listed in Singapore on Nov. 1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。